Aducanumab and the FDA — where are we now?

Nature Reviews Neurology, Published online: 13 January 2021; doi:10.1038/s41582-020-00454-9The amyloid antibody aducanumab is currently undergoing review by the FDA. The treatment would be the first disease-modifying drug to be approved for Alzheimer disease; however, a medical advisory committee recently convened by the FDA did not recommend approval, raising questions about whether the existing evidence of efficacy is sufficient.

Source: Nature Reviews Neurology - January 13, 2021 Category: Neurology Authors: Howard Fillit Allan Green Source Type: research